(Length of video ~17 min)

Thomas Keane discusses strategies to mitigate side effects of ADT therapy and the difference between intermittent vs continuous ADT therapy.  Dr. Keane focuses his lecture on the side effect of hot flashes while undergoing ADT therapy and recommendations for the management of hot flashes.  Also, discussed is bone health and the acceleration of bone loss in men during ADT therapy.    

Related Content:

Watch: Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa- Christopher Sweeney 

Watch: Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: A randomized controlled trial 

Biography:
Thomas E. Keane, MBBCh, FRCSI, FACS